Some of those who are recovering from torn tendons, strained muscles and orthopedic surgery are increasingly turning to injectable compounds called peptides that promise faster healing, and a new federal policy is about to make them easier to get. On October 30, 2026, the U.S. Department of Health and Human Services published a Federal Register notice announcing that it will not take enforcement action against licensed pharmacies and physicians that compound six unapproved peptides, provided they meet ten conditions. The most popular of the six, BPC-157, has never been approved by the FDA for any use and has almost no human research behind it.
Peptides are short chains of amino acids, the building blocks of proteins. Some are well established medicines; insulin and the GLP-1 weight-loss drugs are peptides. The compounds covered by the new policy are different. They have been sold for years online as “research chemicals not for human use,” and they have built a following among athletes, fitness enthusiasts and wellness clinics on the strength of animal studies and social media testimonials. BPC-157 is promoted as the “Wolverine peptide” for tendon, ligament and muscle repair. TB-500 (spoken “T-B five hundred”), a fragment related to a natural protein called thymosin beta-4 (THY-moh-sin BAY-tuh four), is marketed for wound and tissue healing.
The HHS policy, signed by Secretary Robert F. Kennedy Jr., covers BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. It applies to compounding under Section 503A of the federal drug law, the provision that lets state-licensed pharmacies and physicians prepare customized medications for individual patients with a prescription. According to The American Journal of Managed Care, the conditions require that the raw ingredient come from an FDA-registered manufacturer with a certificate of analysis showing identity, purity and potency, that each product contain only one active ingredient, that it be labeled as a compounded drug, and that serious adverse events be reported to the FDA. Each peptide is limited to particular routes; BPC-157, for example, may be compounded for injection under the skin or into muscle, by mouth or for topical use.
It is important to be precise about what the policy does. It is not FDA approval, and it does not add the peptides to the official list of ingredients that pharmacies may lawfully use in compounding. It is a statement that HHS does not intend to enforce the law against compounders who follow its conditions while the FDA decides, through rulemaking whether each substance belongs on that list. HHS says the goal is to steer users away from gray-market products made overseas toward a more controlled source. The policy is labeled a draft, HHS may revisit it if safety or quality problems emerge, and comments were due two weeks after publication.
The decision overrode the agency’s own scientists. In July, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157, KPV and TB-500 for the compounding list, and ultimately recommended six of the seven peptides it reviewed, after career FDA reviewers had recommended against all seven. CNN reported that FDA officials warned their scientific staff would not support a regulation deeming the peptides safe, and that Kennedy has called himself a fan of peptides and has described using BPC-157 for a muscle injury.
The clinical evidence is thin. FDA briefing materials found the available studies, including five on BPC-157, too short and small to establish safety or effectiveness. In a November 5 commentary in Healio’s Orthopedics Today, the authors noted that most BPC-157 animal research comes from a single laboratory, none of it has examined healing after surgical repair, and the human evidence consists of a single case series. The first randomized, placebo-controlled pilot study, in patients after rotator cuff repair, is not scheduled to begin until January 2027. In a separate Healio feature, sports medicine surgeon Jason Dragoo said there is really no human clinical data showing BPC-157 improves healing or performance. Researchers have also debated whether the peptide’s tendency to stimulate new blood vessel growth, called angiogenesis could carry long-term risks.
Use is climbing regardless. A preprint analysis of clinical notes found newly confirmed BPC-157 users rose about 33-fold between early 2020 and early 2026, and about a third of those who documented a source obtained it from gray-market vendors. Product quality is a real concern: an obesity medicine specialist told AJMC that gray-market peptides often contain 5 to 75 percent of the labeled amount, and some carry contaminants. The FDA’s adverse event database has logged 10 serious reports tied to BPC-157 since 2021, eight of them in 2026, though such reports do not prove the drug caused the problem. BPC-157 and TB-500 are also on the World Anti-Doping Agency’s prohibited list.
The workers’ compensation implications start with treatment requests. Some treating physicians, particularly in sports medicine and wellness-oriented practices, may now request authorization for compounded BPC-157 or TB-500 after tendon and soft-tissue injuries. Utilization reviewers will be weighing products that are not FDA approved for any indication and lack published human trials in musculoskeletal healing, against evidence-based treatment standards such as California’s Medical Treatment Utilization Schedule. The workers’ compensation system has a long history of disputes over compounded medications, and payers will want to know the dispensing pharmacy, the source of the raw ingredient and whether the product meets the policy’s conditions. The federal policy does not require any payer to cover these drugs, and AJMC notes that compounded drugs generally fall outside standard pharmacy benefits.
The second issue is undisclosed self-treatment. Because BPC-157 has no national drug code, it never appears on a structured medication list or a pharmacy claim. Many injured users are buying peptides on their own. and may not mention them to a surgeon or a claims examiner. Surgeons are now being urged to ask about peptide use before operating, and claims professionals reviewing pre-operative records may want to see whether that question was asked.
The policy remains in effect until the FDA finishes rulemaking on each peptide, a process AJMC says can take 12 to 24 months, and it could be revised sooner if safety signals emerge. The rotator cuff pilot trial in 2027 may offer the first controlled human data relevant to work injuries. Until then, claims professionals should treat peptides as an unproven, self-directed treatment that is becoming easier to obtain, and ask about it early when soft-tissue injuries and orthopedic surgery are involved.